Which has preferable earnings & valuation, ACXP or PSTV?

Plus Therapeutics is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acurx Pharmaceuticals N/A N/A -$7.97M -$4.05 N/A Plus Therapeutics N/A N/A -$22.39M -$2.30 N/A

Does the media refer more to ACXP or PSTV?

In the previous week, Acurx Pharmaceuticals had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 2 mentions for Acurx Pharmaceuticals and 1 mentions for Plus Therapeutics. Acurx Pharmaceuticals' average media sentiment score of 0.00 equaled Plus Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acurx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ACXP or TXMD?

Acurx Pharmaceuticals presently has a consensus price target of $31.00, suggesting a potential upside of 1,926.14%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, ACXP or PLRZ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acurx Pharmaceuticals N/A N/A -$7.97M -$4.05 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is ACXP or PLRZ more profitable?

Polyrizon's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acurx Pharmaceuticals N/A -153.92% -101.69% Polyrizon N/A N/A N/A

Which has better earnings & valuation, CLRB or ACXP?

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A Acurx Pharmaceuticals N/A N/A -$7.97M -$4.05 N/A

Is CLRB or ACXP more profitable?

Acurx Pharmaceuticals' return on equity of -153.92% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -349.24% -153.18% Acurx Pharmaceuticals N/A -153.92% -101.69%

Acurx Pharmaceuticals (ACXP) Competitors

$1.53 -0.01 (-0.65%)

As of 04:00 PM Eastern

Compare

ACXP vs. PSTV, AYTU, TXMD, PLRZ, and CLRB

Should you buy Acurx Pharmaceuticals stock or one of its competitors? Acurx Pharmaceuticals's main competitors and comparable companies include Plus Therapeutics (PSTV), Aytu BioPharma (AYTU), TherapeuticsMD (TXMD), Polyrizon (PLRZ), and Cellectar Biosciences (CLRB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Acurx Pharmaceuticals compare to Plus Therapeutics?

Acurx Pharmaceuticals (NASDAQ:ACXP) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

In the previous week, Acurx Pharmaceuticals had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 2 mentions for Acurx Pharmaceuticals and 1 mentions for Plus Therapeutics. Acurx Pharmaceuticals' average media sentiment score of 0.00 equaled Plus Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acurx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Acurx Pharmaceuticals has a beta of -2.03, indicating that its share price is 303% less volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 20.3% of Acurx Pharmaceuticals shares are owned by company insiders. Comparatively, 2.5% of Plus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Acurx Pharmaceuticals presently has a consensus price target of $31.00, indicating a potential upside of 1,926.14%. Plus Therapeutics has a consensus price target of $56.40, indicating a potential upside of 1,372.58%. Given Acurx Pharmaceuticals' higher probable upside, equities research analysts plainly believe Acurx Pharmaceuticals is more favorable than Plus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Plus Therapeutics is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A

Acurx Pharmaceuticals has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Acurx Pharmaceuticals' return on equity of -153.92% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Summary

Acurx Pharmaceuticals beats Plus Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Aytu BioPharma?

Aytu BioPharma (NASDAQ:AYTU) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Aytu BioPharma has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.03, suggesting that its share price is 303% less volatile than the broader market.

Aytu BioPharma presently has a consensus price target of $10.75, suggesting a potential upside of 351.68%. Acurx Pharmaceuticals has a consensus price target of $31.00, suggesting a potential upside of 1,926.14%. Given Acurx Pharmaceuticals' higher possible upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Acurx Pharmaceuticals has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

In the previous week, Acurx Pharmaceuticals had 2 more articles in the media than Aytu BioPharma. MarketBeat recorded 2 mentions for Acurx Pharmaceuticals and 0 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 0.00 equaled Acurx Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Aytu BioPharma	Neutral
Acurx Pharmaceuticals	Neutral

Acurx Pharmaceuticals has lower revenue, but higher earnings than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.38	-$13.56M	-$4.58	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

Summary

Acurx Pharmaceuticals beats Aytu BioPharma on 7 of the 13 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to TherapeuticsMD?

Acurx Pharmaceuticals (NASDAQ:ACXP) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Acurx Pharmaceuticals has a beta of -2.03, suggesting that its stock price is 303% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

TherapeuticsMD has higher revenue and earnings than Acurx Pharmaceuticals. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A
TherapeuticsMD	$3.02M	7.93	-$570K	$0.06	34.50

In the previous week, Acurx Pharmaceuticals had 2 more articles in the media than TherapeuticsMD. MarketBeat recorded 2 mentions for Acurx Pharmaceuticals and 0 mentions for TherapeuticsMD. Acurx Pharmaceuticals' average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
Acurx Pharmaceuticals	Neutral
TherapeuticsMD	Neutral

TherapeuticsMD has a net margin of 5.34% compared to Acurx Pharmaceuticals' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
TherapeuticsMD	5.34%	0.32%	0.23%

Acurx Pharmaceuticals presently has a consensus price target of $31.00, suggesting a potential upside of 1,926.14%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 20.3% of Acurx Pharmaceuticals shares are held by insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

TherapeuticsMD beats Acurx Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Polyrizon?

Acurx Pharmaceuticals (NASDAQ:ACXP) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

In the previous week, Acurx Pharmaceuticals had 2 more articles in the media than Polyrizon. MarketBeat recorded 2 mentions for Acurx Pharmaceuticals and 0 mentions for Polyrizon. Acurx Pharmaceuticals' average media sentiment score of 0.00 equaled Polyrizon'saverage media sentiment score.

Company	Overall Sentiment
Acurx Pharmaceuticals	Neutral
Polyrizon	Neutral

Polyrizon's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
Polyrizon	N/A	N/A	N/A

Acurx Pharmaceuticals has a beta of -2.03, suggesting that its share price is 303% less volatile than the broader market. Comparatively, Polyrizon has a beta of -1.5, suggesting that its share price is 250% less volatile than the broader market.

Acurx Pharmaceuticals presently has a consensus price target of $31.00, indicating a potential upside of 1,926.14%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Acurx Pharmaceuticals is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 20.3% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Summary

Acurx Pharmaceuticals beats Polyrizon on 6 of the 10 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

In the previous week, Acurx Pharmaceuticals had 2 more articles in the media than Cellectar Biosciences. MarketBeat recorded 2 mentions for Acurx Pharmaceuticals and 0 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.00 equaled Acurx Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Cellectar Biosciences	Neutral
Acurx Pharmaceuticals	Neutral

Acurx Pharmaceuticals' return on equity of -153.92% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

Cellectar Biosciences has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.03, suggesting that its stock price is 303% less volatile than the broader market.

Cellectar Biosciences currently has a consensus price target of $11.00, suggesting a potential upside of 323.08%. Acurx Pharmaceuticals has a consensus price target of $31.00, suggesting a potential upside of 1,926.14%. Given Acurx Pharmaceuticals' higher probable upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by company insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Acurx Pharmaceuticals beats Cellectar Biosciences on 8 of the 13 factors compared between the two stocks.

Get Acurx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACXP vs. The Competition

Export

Metric	Acurx Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.62M	$11.84B	$7.02B	$12.98B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-0.38	649.40	210.34	20.96
Price / Sales	N/A	740.84	588.78	86.31
Price / Cash	N/A	15.12	28.89	37.42
Price / Book	0.74	10.33	11.27	6.42
Net Income	-$7.97M	$2.77B	$3.45B	$347.03M
7 Day Performance	6.99%	2.04%	3.56%	2.48%
1 Month Performance	2.00%	-1.57%	-0.58%	-1.04%
1 Year Performance	-65.77%	191.33%	77.52%	23.22%

Acurx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACXP Acurx Pharmaceuticals	2.7431 of 5 stars	$1.53 -0.6%	$31.00 +1,926.1%	-65.5%	$6.62M	N/A	N/A	3	News Coverage Upcoming Earnings Gap Up
PSTV Plus Therapeutics	1.7929 of 5 stars	$3.52 -9.0%	$56.40 +1,502.3%	-80.7%	$24.22M	$5.21M	N/A	20	Upcoming Earnings Gap Down
AYTU Aytu BioPharma	1.8023 of 5 stars	$2.21 -1.8%	$10.75 +386.4%	-0.4%	$24.15M	$66.38M	N/A	160
TXMD TherapeuticsMD	1.1671 of 5 stars	$2.04 flat	N/A	+94.4%	$23.61M	$3.02M	34.00	420	Upcoming Earnings
PLRZ Polyrizon	0.4445 of 5 stars	$10.20 -3.7%	N/A	+65.5%	$22.07M	N/A	N/A	N/A	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACXP) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acurx Pharmaceuticals (ACXP) Competitors

ACXP vs. PSTV, AYTU, TXMD, PLRZ, and CLRB

How does Acurx Pharmaceuticals compare to Plus Therapeutics?

Summary

How does Acurx Pharmaceuticals compare to Aytu BioPharma?

Summary

How does Acurx Pharmaceuticals compare to TherapeuticsMD?

Summary

How does Acurx Pharmaceuticals compare to Polyrizon?

Summary

How does Acurx Pharmaceuticals compare to Cellectar Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP vs. The Competition

Acurx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acurx Pharmaceuticals (ACXP) Competitors

ACXP vs. PSTV, AYTU, TXMD, PLRZ, and CLRB

How does Acurx Pharmaceuticals compare to Plus Therapeutics?

Does the media refer more to ACXP or PSTV?

Which has more volatility & risk, ACXP or PSTV?

Do institutionals & insiders believe in ACXP or PSTV?

Do analysts prefer ACXP or PSTV?

Which has preferable earnings & valuation, ACXP or PSTV?

Is ACXP or PSTV more profitable?

Summary

How does Acurx Pharmaceuticals compare to Aytu BioPharma?

Do institutionals and insiders have more ownership in AYTU or ACXP?

Which has more risk and volatility, AYTU or ACXP?

Do analysts recommend AYTU or ACXP?

Is AYTU or ACXP more profitable?

Does the media favor AYTU or ACXP?

Which has stronger valuation & earnings, AYTU or ACXP?

Summary

How does Acurx Pharmaceuticals compare to TherapeuticsMD?

Which has more risk & volatility, ACXP or TXMD?

Which has higher earnings & valuation, ACXP or TXMD?

Does the media refer more to ACXP or TXMD?

Is ACXP or TXMD more profitable?

Do analysts recommend ACXP or TXMD?

Do insiders & institutionals have more ownership in ACXP or TXMD?

Summary

How does Acurx Pharmaceuticals compare to Polyrizon?

Does the media refer more to ACXP or PLRZ?

Is ACXP or PLRZ more profitable?

Which has more volatility and risk, ACXP or PLRZ?

Do analysts prefer ACXP or PLRZ?

Do institutionals and insiders believe in ACXP or PLRZ?

Which has preferable earnings & valuation, ACXP or PLRZ?

Summary

How does Acurx Pharmaceuticals compare to Cellectar Biosciences?

Does the media prefer CLRB or ACXP?

Is CLRB or ACXP more profitable?

Which has better earnings & valuation, CLRB or ACXP?

Which has more volatility & risk, CLRB or ACXP?

Do analysts rate CLRB or ACXP?

Do institutionals & insiders hold more shares of CLRB or ACXP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP vs. The Competition

Acurx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools